The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease
Open accessAbstract
Background & aims Non-alcoholic and alcohol-related fatty liver disease are overlapping diseases in which metabolic syndrome and alcohol consumption each contribute to progressive liver disease. We aimed to assess the effects of alcohol consumption and metabolic syndrome on mortality in individuals with fatty liver.Methods We searched the National Health and Nutrition and Examination Survey III for adults (20-74 years old) with hepatic steatosis, detected by ultrasound, for whom mortality and follow-up data were available. We collected data from the alcohol use questionnaire (self-reported number of days a participant drank alcohol; the number of drinks [10 g alcohol] per day on a drinking day; the number of days the participant had 5 or more drinks) and calculated the average amount of alcohol consumption in drinks/day for each participant during the year preceding enrollment. Excessive alcohol consumption for men was >3 drinks/day and for women was >1.5 drinks/day. We also collected clinical data, and mortality data were obtained from the National Death Index. Demographic and clinical parameters were compared among consumption groups using the χ 2 test for independence or survey regression models. We used Cox proportional hazard models to identify independent predictors of all-cause and cause-specific mortality.Results The study cohort included 4264 individuals with hepatic steatosis (mean age, 45.9 years; 51% male; 76% white; 46% with metabolic syndrome; 6.2% with excessive alcohol use). There was no significant difference in mean age between individuals with vs without excessive alcohol consumption (P=.65). However, overall mortality was significantly higher among participants with excessive alcohol consumption (32.2%) vs participants with non-excessive alcohol use (22.2%) after mean 20 years of follow up (P=.003), as well as after 5 years of follow up. In multivariate analysis, the presence of metabolic syndrome (adjusted hazard ratio [aHR], 1.43; 95% CI, 1.12-1.83) and excessive alcohol consumption (aHR, 1.79; 95% CI, 1.21-2.66) were independently associated with an increased risk of death in individuals with hepatic steatosis; any lower average amount of alcohol consumption was not associated with mortality (all P>.60). In a subgroup analysis, the association of excessive alcohol use with mortality was significant in individuals with metabolic syndrome (aHR, 2.46; 95% CI, 1.40-4.32) but not without it (P=.74).Conclusion In review of data from the National Health and Nutrition and Examination Survey III, we associated alcohol consumption with increased mortality in participants with fatty liver and metabolic syndrome. These findings indicate an overlap between non-alcoholic and alcohol-related fatty liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Earlier cohort and cross-sectional studies on individuals with non-cirrhotic MASLD showed no effect or even protective effects of lowmoderate alcohol consumption on overall mortality, MASLD and steatohepatitis.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [87]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with non-cirrhotic MASLD the evidence for low or moderate alcohol consumption is con fl icting.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [87]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021
Estes, C., Razavi, H. A., Loomba, R. S., Younossi, Z. M., & Sanyal, A. J. (2017) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,496
Wong, R. J., Aguilar, M. E. F., Cheung, R. C., Perumpail, R. B., Harrison, S. A., Younossi, Z. M., & Ahmed, A. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.11.039 · Cited by 1,861
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe
Younossi, Z. M., Blissett, D. B., Blissett, R., Henry, L. L., Stepanova, M., Younossi, Y., Racila, A., Hunt, S., & Beckerman, R. (2016) · Hepatology · doi:10.1002/hep.28785 · Cited by 1,308
Younossi, Z. M., Stepanova, M., Afendy, M., Fang, Y. H., Younossi, Y., Mir, H., & Srishord, M. K. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.03.020 · Cited by 1,072
Younossi, Z. M., Otgonsuren, M., Henry, L., Venkatesan, C., Mishra, A., Erario, M., & Hunt, S. (2015) · Hepatology · doi:10.1002/hep.28123 · Cited by 802
Self-citationYounossi, Z., Stepanova, M., Ong, J., Jacobson, I., Bugianesi, E., Duseja, A., Eguchi, Y., Wong, V., Negro, F., Yılmaz, Y., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.05.057 · Cited by 702
Lorenzo, C., Williams, K., Hunt, K. J., & Haffner, S. M. (2006) · Diabetes Care · doi:10.2337/dc06-1414 · Cited by 669
Nonalcoholic fatty liver disease in patients with type 2 diabetes
Younossi, Z. M., Gramlich, T., Matteoni, C. A., Boparai, N., & McCullough, A. J. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00014-x · Cited by 443
Younossi, Z., & Henry, L. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.005 · Cited by 334
Self-citationDunn, W., Sanyal, A. J., Brunt, E. M., Ünalp–Arida, A., Donohue, M., McCullough, A. J., & Schwimmer, J. B. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.03.024 · Cited by 279
Golabi, P., Fazel, S., Otgonsuren, M., Sayıner, M., Locklear, C. T., & Younossi, Z. M. (2017) · Medicine · doi:10.1097/md.0000000000005904 · Cited by 257
Prognostic factors in alcoholic liver disease. VA Cooperative Study Group.
Chedid, A., Mendenhall, C. L., Gartside, P. S., French, S. W., Chen, T., & Rabin, L. (1991) · PubMed · Cited by 214
Final results of a long-term, clinical follow-up in fatty liver patients
Dam‐Larsen, S., Becker, U., Franzmann, M., Larsen, K. R., Christoffersen, P., & Bendtsen, F. (2009) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520903171284 · Cited by 187
Ajmera, V. H., Belt, P. H., Wilson, L., Gill, R. M., Loomba, R. S., Kleiner, D. E., Neuschwander‐Tetri, B. A., & Terrault, N. A. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.01.026 · Cited by 157
Fibrosis progression occurs in a subgroup of heavy drinkers with typical histological features
Mathurin, P., Beuzin, F., Louvet, A., Ganne‐Carrié, N., Balian, A., Trinchet, J.-C., Soglio, D. B. D., Prevot, S., & Naveau, S. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03302.x · Cited by 151
Golabi, P., Otgonsuren, M., Cable, R., Felix, S. C., Koenig, A. B., Sayıner, M., & Younossi, Z. M. (2016) · Health and Quality of Life Outcomes · doi:10.1186/s12955-016-0420-z · Cited by 147
Hajifathalian, K., Torabi Sagvand, B., & McCullough, A. J. (2019) · Hepatology · doi:10.1002/hep.30226 · Cited by 128
Roles of alcohol consumption in fatty liver: A longitudinal study
Moriya, A., Iwasaki, Y., Ohguchi, S., Kayashima, E., Mitsumune, T., Taniguchi, H., Ando, M., & Yamamoto, K. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.11.025 · Cited by 112
Loomba, R. S., Bettencourt, R., & Barrett-Connor, E. L. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04141.x · Cited by 110
Kwon, H. K., Greenson, J. K., & Conjeevaram, H. S. (2013) · Liver International · doi:10.1111/liv.12230 · Cited by 99
Flagged first, then by citations
Cited by
Sorted by citations
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Changing epidemiology, global trends and implications for outcomes of NAFLD
Wong, V. W.-S., Ekstedt, M., Wong, G. L.-H., & Hagström, H. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.036 · Cited by 765
Epidemiology of chronic liver diseases in the USA in the past three decades
Younossi, Z. M., Stepanova, M., Younossi, Y., Golabi, P., Mishra, A., Rafiq, N., & Henry, L. L. (2019) · Gut · doi:10.1136/gutjnl-2019-318813 · Cited by 550
(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 545
Metadata
- Authors
- Younossi, Z. M., Stepanova, M., Ong, J., Yilmaz, Y., Duseja, A., Eguchi, Y., El Kassas, M., Castellanos-Fernandez, M., George, J., Jacobson, I. M., Bugianesi, E., Wong, V. W.-S., Arrese, M., de Ledinghen, V., Romero-Gomez, M., Mendez-Sanchez, N., Ahmed, A., Wong, R., Papatheodoridis, G., Serfaty, L., Younossi, I., Nader, F., Ziayee, M., & Afendy, A.
- Affiliations
- Inova Health System (US)
- Center for Outcomes Research in Liver Diseases (US)
- University of the Philippines Manila (PH)
- Marmara University (TR)
- Post Graduate Institute of Medical Education and Research (IN)
- Saga University (JP)
- The University of Sydney (AU)
- NYU Langone Health (US)
- University of Turin (IT)
- Chinese University of Hong Kong (HK)
- Pontificia Universidad Católica de Chile (CL)
- Stanford Medicine (US)
- Alameda Health System (US)
- Hôpital d'Hautepierre (FR)
- Corresponding author
- Younossi, Zobair M.
- ORCID
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 17
- Issue
- 8
- Pages
- 1625-1633.e1
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W2901363517
- Cited by
- 172
- References
- 23
- Citations by year
- 2026: 13 · 2025: 18 · 2024: 37 · 2023: 23 · 2022: 19 · 2021: 22 · 2020: 24 · 2019: 16
- FWCI
- 12.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Gastroenterology and Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion, other-oa)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Funders
- Center for Outcomes Research in Liver Disease
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- non-alcoholic fatty liver disease, hepatic steatosis, alcohol consumption, metabolic syndrome, mortality, excessive drinking, all-cause mortality, cause-specific mortality, liver disease progression, NHANES III, mortality risk factors, alcohol screening and brief intervention
- MeSH terms
- Adult, Aged, Alcohol Drinking, Female, Follow-Up Studies, Humans, Liver Cirrhosis, Alcoholic, Male, Middle Aged, Prognosis, Retrospective Studies, Risk Factors, United States, Incidence, Survival Rate, Disease Progression, Metabolic Syndrome, Young Adult, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review